2 tracked public figures made calls on VYGR.
Every pick graded against the S&P 500 over matching windows.
Total Calls
2
2 buy · 0 sell
Avg Buy Return
-22.8%
vs S&P +7.4%
Best Buy Call
-22.8%
Charlie Scharf · Mar 2026
Figures Tracked
2
public figures with VYGR calls
Is VYGR a Buy or Sell?
Public buy calls on Voyager Therapeutics have underperformed the S&P 500.
On average, public BUY calls on Voyager Therapeutics underperformed the S&P 500 by +30.2%.
Voyager Therapeutics Stock Prediction Track Records
GotReceipts tracks public buy and sell signals for Voyager Therapeutics (VYGR)
and measures outcomes over matched windows.
For this ticker model, performance vs the S&P 500 is based on BUY/ADD calls only.
SELL/REDUCE calls are graded directionally and shown as Correct, Incorrect, or Pending.
That way, you can quickly see whether following public buy calls added value versus simply holding the index.
Do VYGR stock predictions beat the S&P 500?
No. Across 2 scored BUY/ADD calls, average return is -22.8% versus +7.4% for the S&P 500, for -30.2% alpha.
Who has the best track record predicting Voyager Therapeutics?
Charlie Scharf currently ranks #1 on VYGR, with -22.8% average buy return versus +7.4% for the S&P 500 (-30.2% alpha) across 1 scored buy calls.
Is VYGR overvalued or undervalued?
Public prediction track records currently lean cautious on VYGR: buy calls have underperformed the index by +30.2% on average.
Should I follow analyst ratings on VYGR?
Use analyst and public-figure calls as one input, not a standalone signal. GotReceipts shows historical outcomes versus the S&P 500 so you can judge signal quality before acting.